Sinovac Applies to Begin Mumps Vaccine Trial

Sinovac Biotech (北京科兴生物制品有限公司) said its subsidiary Sinovac Dalian, a JV formed in January 2010, has applied to the SFDA to begin clinical trials of a mumps vaccine. The application is the first from the JV and also the first live attenuated vaccine from Sinovac. Sinovac has vaccines for measles and rubella in the works, which it plans to combine into a measles, mumps, rubella (MMR) vaccine for government purchasing. More details... Stock Symbol: (NSDQ: SVA)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.